| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/2326-6066.CIR-15-0151 |
| P698 | PubMed publication ID | 26546453 |
| P50 | author | Gordon J. Freeman | Q27088375 |
| Arlene Sharpe | Q58235901 | ||
| David A Reardon | Q73570385 | ||
| F Stephen Hodi | Q90321337 | ||
| Patrick Y Wen | Q105531697 | ||
| P2093 | author name string | Xiaoyun Liao | |
| Jun Zhou | |||
| Nancy E Kohl | |||
| Keith L Ligon | |||
| Scott J Rodig | |||
| Prafulla C Gokhale | |||
| Lei Qin | |||
| Glenn Dranoff | |||
| Shakti H Ramkissoon | |||
| Sarah R Klein | |||
| Kristen L Jones | |||
| Amy Saur Conway | |||
| Annick D Van Den Abbeele | |||
| P433 | issue | 2 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 124-135 | |
| P577 | publication date | 2015-11-06 | |
| P1433 | published in | Cancer Immunology Research | Q26841983 |
| P1476 | title | Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model | |
| P478 | volume | 4 |
| Q90273455 | A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol |
| Q33772355 | Actionable molecular biomarkers in primary brain tumors |
| Q52659572 | Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma. |
| Q39030177 | Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma |
| Q47569046 | Advances in immunotherapeutic research for glioma therapy. |
| Q38777058 | Advances in the molecular genetics of gliomas - implications for classification and therapy |
| Q90215360 | An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments |
| Q41762827 | An immunocompetent mouse model of human glioblastoma |
| Q57045120 | Arming an oncolytic herpes simplex virus Type 1 with a single chain fragment variable antibody against PD-1 for experimental glioblastoma therapy |
| Q52731750 | Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. |
| Q92965176 | Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy |
| Q91736550 | Brain immunology and immunotherapy in brain tumours |
| Q89573873 | CAR T cells and checkpoint inhibition for the treatment of glioblastoma |
| Q92245332 | CAR T cells for brain tumors: Lessons learned and road ahead |
| Q91785257 | CD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2 |
| Q26740520 | CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas |
| Q55259532 | CNS cancer immunity cycle and strategies to target this for glioblastoma. |
| Q47862082 | CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. |
| Q46900302 | Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. |
| Q64254749 | Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma |
| Q38691679 | Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. |
| Q92369142 | Characterization of transcriptome profile and clinical features of a novel immunotherapy target CD204 in diffuse glioma |
| Q38838646 | Checkpoint inhibition in meningiomas |
| Q90220119 | Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors |
| Q38909071 | Concepts in glioma immunotherapy |
| Q38771020 | Correlation of immune phenotype with IDH mutation in diffuse glioma. |
| Q92457071 | Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma |
| Q50109459 | Current state and future prospects of immunotherapy for glioma |
| Q55457323 | Current state of immunotherapy for glioblastoma. |
| Q59342675 | Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade |
| Q38851464 | Developing immunotherapeutic strategies to target brain tumors |
| Q55283310 | Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. |
| Q97543542 | Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model |
| Q90468503 | Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma |
| Q58545426 | Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas |
| Q46217247 | Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach |
| Q36017728 | Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic ketogenic diet |
| Q47382765 | Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. |
| Q42973443 | Focused Ultrasound Immunotherapy for Central Nervous System Pathologies: Challenges and Opportunities |
| Q97069912 | GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models |
| Q38597700 | Glioblastoma targeted therapy: updated approaches from recent biological insights |
| Q89767107 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
| Q33656811 | History and current state of immunotherapy in glioma and brain metastasis |
| Q50074883 | ID(H)entifying checkpoint inhibitor candidates among diffuse glioma |
| Q52676452 | IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. |
| Q39147759 | Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma |
| Q38743793 | Immune Checkpoint Inhibitors in Gliomas. |
| Q58573409 | Immune Checkpoints and Innovative Therapies in Glioblastoma |
| Q38907925 | Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma |
| Q47866350 | Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas |
| Q47915209 | Immunotherapies for malignant glioma. |
| Q28078539 | Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? |
| Q90218743 | Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas |
| Q90640719 | Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens |
| Q40082476 | Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade |
| Q48344360 | Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide |
| Q47215596 | Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells |
| Q89472896 | Multidimensional communication in the microenvirons of glioblastoma |
| Q62745893 | Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma |
| Q91451450 | Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma |
| Q43749590 | Neutrophils in Gliomas. |
| Q46675575 | Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. |
| Q56891439 | Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma |
| Q64077357 | PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models |
| Q38711929 | PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. |
| Q50423292 | Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade |
| Q90028511 | Potential Effect of Immunotherapy Agents on Cognitive Function in Cancer Patients |
| Q92237972 | Potential for Nuclear Medicine Therapy for Glioblastoma Treatment |
| Q90141422 | Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody |
| Q38438763 | Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. |
| Q47827127 | Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma |
| Q57798069 | RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma |
| Q47140355 | Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. |
| Q54213332 | Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System® (RTS®) gene switch as gene therapy for the treatment of glioma. |
| Q57158493 | Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience |
| Q90326744 | Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models |
| Q92881287 | Revealing and Harnessing Tumour-Associated Microglia/Macrophage Heterogeneity in Glioblastoma |
| Q37672257 | Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma |
| Q38771929 | Special topics in immunotherapy and radiation therapy: reirradiation and palliation |
| Q89486322 | Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate |
| Q26750891 | Systemic Immunotherapy for the Treatment of Brain Metastases |
| Q89685712 | T lymphocyte-targeted immune checkpoint modulation in glioma |
| Q90417081 | T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
| Q38909389 | The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma |
| Q99238181 | The Role of NK Cells and Innate Lymphoid Cells in Brain Cancer |
| Q92644024 | The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018 |
| Q90057920 | Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine |
| Q91868339 | Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma |
| Q50083504 | Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFNβ in Glioblastomas. |
| Q64075498 | Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers |
| Q38789860 | Vaccine-based immunotherapeutic approaches to gliomas and beyond |
| Q88231951 | Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules |
Search more.